Table 2.
Overview of osteopontin levels measured with commercially available ELISA systems in healthy controls, malignant and benign diseases.
| assay | material | patient group (n) | osteopontin mean ± SD (ng/ml) | osteopontin median (range) (ng/ml) | ref. |
| Assay Designs (B1) | citrate plasma | head and neck cancer (54) von Hippel Lindau disease (31) healthy controls (15) | 447 (261–843) 318 (233–461) | 450 | [1] |
| plasma | head and neck cancer (320) | -- | 113 (12–1382) | [2] | |
| plasma | nasopharyngeal cancer healthy controls | 184.6 (6.8–856.9) 75.9 (10–455) |
-- -- |
[18] | |
| EDTA plasma | multiple sclerosis – relapsing patients (30) healthy controls (10) |
-- -- |
280 174 |
[17] | |
| serum | ovarian cancer (51) healthy controls (28) |
49 11 |
-- -- |
[19] | |
| IBL (B2) | serum | pleural mesothelioma (76) asbestos-related non-malignant disease (69) healthy controls (45) |
133 ± 10 30 ± 3 20 ± 4 |
-- -- -- |
[5] |
| EDTA plasma | esophageal carcinoma (103) | -- | 606 (82.8–1980) | [20] | |
| plasma | ovarian cancer (51) healthy controls (107) |
486.5 147.1 |
-- -- |
[21] | |
| plasma | ovarian cancer (38) | -- | 178 (12–3468) | [22] | |
| serum | ovarian cancer, post-surgery (267) healthy controls (67) |
74 ± 116 147 ± 192 |
25 (25–671) 85 (25–617) |
[23] | |
| heparin plasma | non-small lung cancer (158) benign pulmonary disease (54) healthy controls (25) |
356.2 175.6 29.5 |
319.1 (16–1600) 161.6 (1.3–442.8) 17.9 (0–102.8) |
[24] | |
| EDTA plasma | coronary artery disease (107) healthy controls (71) |
616 ± 308 443 ± 237 |
-- -- |
[16] | |
| EDTA plasma | interstitial pneumonia (17) healthy controls (20) |
945 ± 256 156.7 ± 52.2 |
-- -- |
[15] |